Prevention of Recurrent Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Systematic Review and Meta-Analysis of Randomized Trials
Prevention of Recurrent Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers: A Systematic Review and Meta-Analysis of Randomized Trials
复制标题
DOI：
10.1177/1074248410389045
复制
发表时间：
2011-06-01
影响因子：
2.6
通讯作者：
Arora, Rohit
中科院分区：
文献类型：
--
作者：
Bhuriya, Rohit;Singh, Mukesh;Arora, Rohit
背景：关于血管紧张素转换酶抑制剂（ACEIs）和血管紧张素受体阻滞剂（ARB）预防复发性心房颤动（AF）的功效仍然存在争议。我们对随机对照试验 (RCT) 进行了荟萃分析，旨在探讨 ACE 和 ARB 是否可以减少 AF 复发，而该试验并非事先设计来检验这一假设。方法：我们对使用 ACEI 或 ARB 的随机对照试验进行了系统的文献检索，并提供了有关复发性房颤结果的数据。使用 Cochran Q 统计量测试整个试验的统计异质性，并计算 I-2 以量化异质性。小于 0.05 的 2 边误差被认为具有统计显着性（P
Background: Controversy persists regarding the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in the prevention of recurrent atrial fibrillation (AF). We performed a meta-analysis of randomized controlled trials (RCTs), not designed a priori to test this hypothesis, to explore whether ACEs and ARBs reduce recurrent AF. Methods: We performed a systematic literature search for RCTs using ACEIs or ARBs and providing data on the outcome of recurrent AF. Statistical heterogeneity across the trials was tested using the Cochran Q statistic and I-2 was computed to quantify heterogeneity. A 2-sided a error of less than .05 was considered statistically significant (P